Centaurus Financial’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,287
Closed -$232K 1083
2025
Q4
$232K Sell
2,287
-230
-9% -$18.5K 0.01% 754
2025
Q3
$138K Buy
2,517
+120
+5% +$6K 0.01% 922
2025
Q2
$127K Buy
2,397
+30
+1% +$1.52K 0.01% 873
2025
Q1
$102K Buy
+2,367
New +$120K 0.01% 871
2022
Q1
Sell
-1,605
Closed -$125K 919
2021
Q4
$125K Sell
1,605
-400
-20% -$35.3K 0.01% 826
2021
Q3
$191K Hold
2,005
0.02% 664
2021
Q2
$249K Hold
2,005
0.02% 612
2021
Q1
$264K Buy
2,005
+15
+0.8% +$2.05K 0.03% 535
2020
Q4
$264K Buy
1,990
+30
+2% +$3.63K 0.03% 489
2020
Q3
$200K Buy
+1,960
New +$169K 0.03% 449
2019
Q3
Sell
-1,000
Closed -$118K 489
2019
Q2
$118K Buy
+1,000
New +$101K 0.02% 537
2018
Q3
Sell
-1,500
Closed -$90K 1007
2018
Q2
$90K Buy
+1,500
New +$80.7K 0.01% 743

Other funds holding EXAS

Centaurus Financial's EXAS Position: Q1 2026 in Review

Centaurus Financial sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 2,287 shares — an estimated $232K sold.

Centaurus Financial first reported a position in EXAS in Q2 2018 and held it in 12 quarters. The position peaked at $264K in Q1 2021. 6 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Centaurus Financial reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Centaurus Financial sold 2,287 Exact Sciences shares in Q1 2026, an estimated $232K.
  • Centaurus Financial first reported a position in Exact Sciences in Q2 2018 and held it in 12 quarters.
  • Centaurus Financial's Exact Sciences position peaked at $264K in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.